71.61
price up icon4.49%   3.08
after-market 시간 외 거래: 71.00 -0.61 -0.85%
loading
전일 마감가:
$68.53
열려 있는:
$69.29
하루 거래량:
1.26M
Relative Volume:
0.46
시가총액:
$13.88B
수익:
$502.08M
순이익/손실:
$-732.94M
주가수익비율:
-18.92
EPS:
-3.7842
순현금흐름:
$-455.50M
1주 성능:
+2.12%
1개월 성능:
+7.62%
6개월 성능:
+46.14%
1년 성능:
+94.91%
1일 변동 폭
Value
$68.94
$72.28
1주일 범위
Value
$67.57
$72.35
52주 변동 폭
Value
$28.32
$84.94

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
명칭
Bridgebio Pharma Inc
Name
전화
(650) 391-9740
Name
주소
3160 PORTER DR., PALO ALTO, CA
Name
직원
839
Name
트위터
Name
다음 수익 날짜
2026-02-24
Name
최신 SEC 제출 서류
Name
BBIO's Discussions on Twitter

Compare BBIO vs VRTX, REGN, ALNY, ARGX, INSM

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
BBIO icon
BBIO
Bridgebio Pharma Inc
71.61 13.29B 502.08M -732.94M -455.50M -3.7842
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-03-10 개시 William Blair Outperform
2026-01-28 개시 Barclays Overweight
2026-01-06 개시 Morgan Stanley Overweight
2025-12-11 개시 Bernstein Outperform
2025-07-30 재개 Raymond James Outperform
2025-07-21 개시 Truist Buy
2025-07-14 개시 Jefferies Buy
2025-07-09 업그레이드 Oppenheimer Perform → Outperform
2025-06-17 개시 Wolfe Research Outperform
2025-03-31 개시 Redburn Atlantic Buy
2024-10-16 개시 Scotiabank Sector Outperform
2024-10-03 개시 Oppenheimer Perform
2024-09-04 개시 Piper Sandler Overweight
2024-03-21 재개 Raymond James Outperform
2024-01-31 개시 BMO Capital Markets Market Perform
2023-12-08 개시 Wells Fargo Overweight
2023-11-07 개시 Citigroup Buy
2023-10-24 개시 Cantor Fitzgerald Overweight
2023-07-18 다운그레이드 Jefferies Buy → Hold
2023-04-19 개시 Evercore ISI Outperform
2023-02-06 개시 Cowen Outperform
2021-12-27 재확인 Mizuho Buy
2021-12-27 재확인 SVB Leerink Outperform
2021-09-10 업그레이드 BofA Securities Neutral → Buy
2021-05-21 개시 UBS Buy
2021-03-22 재확인 Goldman Buy
2021-02-22 재개 JP Morgan Overweight
2021-02-09 재개 Goldman Buy
2021-01-11 재확인 H.C. Wainwright Buy
2020-12-10 재확인 H.C. Wainwright Buy
2020-06-25 개시 BofA/Merrill Neutral
2020-05-19 개시 BTIG Research Buy
2020-04-13 개시 H.C. Wainwright Buy
2020-02-19 개시 Mizuho Buy
2019-07-26 개시 Raymond James Outperform
2019-07-22 개시 BMO Capital Markets Outperform
2019-07-22 개시 Goldman Buy
2019-07-22 개시 JP Morgan Overweight
2019-07-22 개시 Jefferies Buy
2019-07-22 개시 Piper Jaffray Overweight
2019-07-22 개시 SVB Leerink Outperform
모두보기

Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스

pulisher
Mar 25, 2026

Market Catalysts: Whats next for BridgeBio Pharma Inc stock2026 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 23, 2026

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - The Manila Times

Mar 23, 2026
pulisher
Mar 23, 2026

BridgeBio heart drug lands late-breaking ACC slot with survival data - Stock Titan

Mar 23, 2026
pulisher
Mar 22, 2026

Aug Retail: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARPortfolio Profit Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 22, 2026
pulisher
Mar 20, 2026

BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

BridgeBio Pharma (BBIO) President and CFO receives 59,041 RSU equity grant - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

BridgeBio (BBIO) CAO awarded 14,170 RSUs in new equity grant - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 20, 2026
pulisher
Mar 20, 2026

BridgeBio gives 29 new hires stock awards totaling 70,916 shares - Stock Titan

Mar 20, 2026
pulisher
Mar 19, 2026

BridgeBio (BBIO) CEO Neil Kumar awarded options and 104,313 RSUs - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Mizuho Raises Price Target on BridgeBio Pharma to $106 From $91, Keeps Outperform Rating - marketscreener.com

Mar 19, 2026
pulisher
Mar 18, 2026

BridgeBio Pharma launches initiative to define age-specific pathways for FGFR3 testing - Traders Union

Mar 18, 2026
pulisher
Mar 18, 2026

Mizuho raises BridgeBio Pharma stock price target on drug strength By Investing.com - Investing.com Canada

Mar 18, 2026
pulisher
Mar 18, 2026

Mizuho raises BridgeBio Pharma stock price target on drug strength - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Mizuho Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

BBIO: Mizuho Raises Price Target to $106, Maintains 'Outperform' Rating | BBIO Stock News - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

Raymond James Maintains BridgeBio Pharma (BBIO) Outperform Recommendation - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

BridgeBio Pharma Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com

Mar 18, 2026
pulisher
Mar 18, 2026

Aug Sectors: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARMarket Performance Summary & Entry Point Strategy Guides - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 17, 2026

Resistance Check: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEAR2026 Trade Ideas & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

BBIO PE Ratio & Valuation, Is BBIO Overvalued - Intellectia AI

Mar 17, 2026
pulisher
Mar 17, 2026

(BBIO) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 17, 2026
pulisher
Mar 17, 2026

Fred Alger Management LLC Has $10.25 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 17, 2026
pulisher
Mar 17, 2026

BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock - Investing.com Nigeria

Mar 17, 2026
pulisher
Mar 16, 2026

BridgeBio Pharma CEO Kumar Neil sells $5.5m in BBIO stock By Investing.com - Investing.com South Africa

Mar 16, 2026
pulisher
Mar 16, 2026

Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

BridgeBio (BBIO) CEO’s family trusts sell 80,000 company shares - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

HighVista Strategies LLC Raises Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Granahan Investment Management LLC Buys 78,588 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Farallon Capital Management LLC Has $425.49 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback - Yahoo Finance

Mar 15, 2026
pulisher
Mar 15, 2026

The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter

Mar 15, 2026
pulisher
Mar 15, 2026

Boone Capital Management LLC Buys Shares of 460,282 BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

Prosight Management LP Sells 208,187 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat

Mar 14, 2026
pulisher
Mar 13, 2026

BBIO6336503 Bond Risk Analysis - TradingView

Mar 13, 2026
pulisher
Mar 13, 2026

BBIO6336503 Bond Coupon Analysis — Rate & Payments - TradingView

Mar 13, 2026
pulisher
Mar 13, 2026

How Positive Phase 3 LGMD Data Could Shape BridgeBio Pharma’s (BBIO) Risk Profile and Upside Potential - simplywall.st

Mar 13, 2026
pulisher
Mar 13, 2026

BBIO (NASDAQ: BBIO) — Trustee and Insider 10b5-1 Sales Listed - Stock Titan

Mar 13, 2026
pulisher
Mar 13, 2026

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Tenet Healthcare (THC) - The Globe and Mail

Mar 13, 2026
pulisher
Mar 13, 2026

BridgeBio Touts Attruby Uptake, Bayer's Europe Rollout, and Pipeline Timelines - National Today

Mar 13, 2026
pulisher
Mar 12, 2026

BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9 - Citeline News & Insights

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio Pharma Director Sells Shares - TradingView

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio director sells 8,671 shares after option exercise | BBIO SEC FilingForm 4 - Stock Titan

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio (BBIO) soars 13% on double-digit price target upgrade - MSN

Mar 12, 2026
pulisher
Mar 12, 2026

A Look At BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - simplywall.st

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio reports Phase III progress for BBP-418 - The Pharma Letter

Mar 12, 2026
pulisher
Mar 12, 2026

BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress - Benzinga

Mar 12, 2026

Bridgebio Pharma Inc (BBIO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
자본화:     |  볼륨(24시간):